


SEW

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: MAIL STOP AMENDMENT, COMMISSIONER OF PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE INDICATED

DELOV.BY: Lisa R. Haines DATE: July 27, 2007



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Gebecki, et al.

Attorney Docket No. 200045-0003-00-US
(405304)

Application No.: 10/585,892

Group Art Unit: To Be Assigned

Filed: July 11, 2006

Examiner: To Be Assigned

Title: THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS

INFORMATION DISCLOSURE UNDER 37 CFR 1.97(b)

Sir:

Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, the Applicant attaches hereto a completed PTO Form 1449 (modified) and, where required, copies of the information cited therein.

**IDENTIFICATION OF TIME OF FILING THIS
INFORMATION DISCLOSURE STATEMENT**

This Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits for the above identified patent application. Accordingly, no certification, petition, or fee is required. However, if a fee is due, please charge, or credit any overcharge to, Deposit Account No. 50-0573.

**IDENTIFICATION OF REFERENCES AND
CONCISE EXPLANATION OF RELEVANCE
OF REFERENCES NOT IN THE ENGLISH LANGUAGE**

Reference DE 840 698 C (Cilag A.G.) 5 July 1952 is cited in the present IDS. Corresponding British patent 675,430 is an English language equivalent of the German patent. As such, no concise explanation is included herewith pursuant to MPEP 609.04(a)(III).

The references listed in this Information Disclosure Statement comprise the most pertinent prior art known to Applicants and their attorneys as of the date hereof. This Information Disclosure Statement should not be construed as a representation that the cited references are material or that no better art exists.


It is respectfully requested that the information be considered by the Examiner and that a copy of the attached Form PTO-1449 be returned indicating that such information has been considered.

In the event any fees are required in connection with this paper, please charge Deposit Account No. 50-0573.

Applicants' undersigned attorney may be reached by telephone at (215) 988.3385. All correspondence should be directed to the below-listed address.

Respectfully submitted,
GEBECKI, *ET AL.*

Date: July 27, 2007


Kathryn Doyle, Ph.D., J.D.
Registration No. 36,317
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Tel: (215) 988.2902
Fax: (215) 988.2757
Attorney for Applicants

JEP



Form PTO-1449
U.S. Department of Commerce
Date Filed: _____

DOCKET NO.
200045-0003-00-US
(405304)

APPLN. NO.
10/585,892

APPLICANT: Gebecki, et al.

FILING DATE: July 11, 2006

GROUP To Be Assigned

U.S. PATENT DOCUMENTS

Initial	Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	2006/0263428	11/23/2006	Cefali			
	2001/0014338	8/16/2001	Cefali			
	2003/0157153	8/21/2003	Cefali			
	2003/0161880	8/28/2003	Cefali			
	2005/0255158	11/17/2005	Bova			
	6,090,830	7/18/2000	Myers, et al.			
	6,129,930	10/10/2000	Bova			
	6,406,715	6/18/2002	Cefali			
	6,469,035	10/22/2002	Cefali			
	6,676,967	1/13/2004	Cefali, et al.			
	6,746,691	1/8/2004	Cefali			
	6,818,229	1/16/2004	Cefali, et al.			
	7,011,848	3/14/2006	Bova			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract
WO/2000/040559	7/13/2000	PCT/IB			
WO/2006/052569	5/18/2006	PCT/US			
DE840698C	6/5/1952	Germany			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, etc.)

	Carlson, L. A. et al, Atherosclerosis, 1972, 16:359-368
	Filetti, S., et al, Endocrinology, 108(6), 2409-2411 (1981)
	Fischer, L. J., et al, Toxicology and Applied Pharmacology 70, 148-155 (1983)
	Fukushima, T. et al, Exp Toxic Pathol 2002; 53: 469-473
	Fukushima, T. et al, Journal of Neuroscience Research 42:385-390 (1995)
	Gebicki, et al, Pol. J. Pharmacol., 2003, 55, 109-112
	Lea, et al, Cancer Biochem Biophys., 1984, vol. 7, 195-202.
	Shibata, et al, Am. J. Clin. Nutr., 1989; 50:114-119
	Taguchi, H., et al., J. Active Oxygens and Free Radicals, v. 14 (1999), pgs. 23-28

Examiner Signature: _____

Date Considered: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).PTO-1449.doc